ARROWHEAD PHARMACEUTICALS, INC. - FORM 10-K - EX-32.1 - SECTION 906 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - December 22, 2009

Attached files

file filename
10-K - FORM 10-K - ARROWHEAD PHARMACEUTICALS, INC.d10k.htm
EX-4.7 - FORM OF WARRANT TO PURCHASE CAPITAL STOCK - ARROWHEAD PHARMACEUTICALS, INC.dex47.htm
EX-4.2 - FORM OF REGISTRATION RIGHTS AGREEMENT - ARROWHEAD PHARMACEUTICALS, INC.dex42.htm
EX-3.4 - CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION - ARROWHEAD PHARMACEUTICALS, INC.dex34.htm
EX-21.1 - LIST OF SUBSIDIARIES - ARROWHEAD PHARMACEUTICALS, INC.dex211.htm
EX-10.8 - AMENDMENT TO EMPLOYMENT AGREEMENT - ARROWHEAD PHARMACEUTICALS, INC.dex108.htm
EX-23.1 - CONSENT OF INDEPENDENT PUBLIC REGISTERED ACCOUNTING FIRM - ARROWHEAD PHARMACEUTICALS, INC.dex231.htm
EX-31.1 - SECTION 302 CERTIFICATION OF CHIEF EXECUTIVE OFFICER - ARROWHEAD PHARMACEUTICALS, INC.dex311.htm
EX-31.2 - SECTION 302 CERTIFICATION OF CHIEF FINANCIAL OFFICER - ARROWHEAD PHARMACEUTICALS, INC.dex312.htm
EX-10.6 - AMENDMENT TO SEVERANCE AGREEMENT - ARROWHEAD PHARMACEUTICALS, INC.dex106.htm
EX-32.2 - SECTION 906 CERTIFICATION OF CHIEF FINANCIAL OFFICER - ARROWHEAD PHARMACEUTICALS, INC.dex322.htm
EX-10.22 - FORM OF SUBSCRIPTION AGREEMENT, DATED AS OF SEPTEMBER 30, 2009 - ARROWHEAD PHARMACEUTICALS, INC.dex1022.htm
EX-10.23 - SECOND AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT - ARROWHEAD PHARMACEUTICALS, INC.dex1023.htm
EX-10.24 - FORM OF SUBSCRIPTION AGREEMENT DATED DECEMBER 11, 2009 - ARROWHEAD PHARMACEUTICALS, INC.dex1024.htm

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b)

OF THE SECURITIES EXCHANGE ACT OF 1934

AND 18 U.S.C. SECTION 1350

I, Christopher Anzalone, Chief Executive Officer of Arrowhead Research Corporation (the “Company”), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that (i) the Annual Report on Form 10-K of the Company for the fiscal year ended September 30, 2009, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii) the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company.

 

Date: December 22, 2009  
 

/s/ CHRISTOPHER ANZALONE

  Christopher Anzalone
  Chief Executive Officer & Principal Executive Officer

A signed original of these written statements required by 18 U.S.C. Section 1350 has been provided to Arrowhead Research Corporation and will be retained by Arrowhead Research Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

Stock widget

Investing forum

ARROWHEAD PHARMACEUTICALS, INC. Reports